---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004237"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:48:22.240747+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund

## Summary
- Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.
- Note convertible at $0.07/share; also issued 1,422,613 warrants at $0.15/share and 1,600,446 commitment shares.
- Note secured against company assets excluding certain JV assets (OT-101, CA4P, Oxi4503, AI technologies).
- Proceeds designated for general working capital; prepayment allowed with 3 trading days' notice.
- Shares issuable upon conversion/exercise not registered; registration rights agreement filed.

## SEC filing metadata
- accession: 0001493152-26-004237
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226004237/0001493152-26-004237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226004237/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004237
- JSON: https://secwatch.observer/filing/0001493152-26-004237.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004237.txt

## Key facts
- Debt Financings
  Oncotelic Therapeutics, Inc. incurred convertible notes of $398,333.33 with Mast Hill Fund, LP at 10% per annum maturing the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a.
  - Instrument: convertible notes
  - Principal: $398,333.33
  - Counterparty: Mast Hill Fund, LP
  - Rate: 10% per annum
  - Maturity: the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a
  - Event: incurrence
  source text: On January 23, 2026, Oncotelic Therapeutics, Inc. (the "Company" or "Our") entered into a Securities Purchase Agreement (the "2026 Mast Hill Purchase Agreement "), with Mast Hill Fund, LP (" Mast Hill "), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the " 2026 Mast Hill Note ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315226004237/0001493152-26-004237-index.htm
- Material Agreements
  Oncotelic Therapeutics, Inc. entered into 2026 Mast Hill Purchase Agreement with Mast Hill Fund, LP valued at $398,333.33 (effective 2026-01-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Mast Hill Fund, LP
  - Value: $398,333.33
  - Effective: 2026-01-23
  source text: On January 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the “ 2026 Mast Hill Note ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315226004237/0001493152-26-004237-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.